FLT1 and neoplasm: The anti-angiogenic drug we used, VEGFR1-Fc, might also have some effects on regulating anti-tumor immunity, as it traps VEGFA, which could inhibit T cells and DCs, as well as promote Treg and MDSC expansion [55].